Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age

Annals of the New York Academy of Sciences

Volumn 1084, Issue , 2006, Pages 166-177

  Kalofoutis, Christos ^a   Piperi, Christina ^a   Zisaki, Aikaterini ^a   Singh, Jaipaul ^b   Harris, Fred ^b   Phoenix, David ^b   Alaveras, Antonis ^a   Kalofoutis, Anastasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Cardiovascular risk factors; Cytokines; Type 2 diabetes mellitus

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; HOMOCYSTEINE;

ADULT; AGE DISTRIBUTION; AGED; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGING; ARTICLE; BLOOD; DIABETIC ANGIOPATHY; METABOLISM; PHYSIOLOGY; REFERENCE VALUE; RISK FACTOR;

ADOLESCENT; ADULT; AGING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; REFERENCE VALUES; RISK FACTORS; TRIGLYCERIDES;

EID: 34447634688     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1372.001     Document Type: Conference Paper

References (50)

1. FORD, E.S. et al. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359.
2. CARO, J.J. et al. 2002. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 25: 476-481.
3. MUNTNER, P. et al. 2004. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann. Epidemiol. 14: 686-695.
4. PYORALA, K. et al. 1987. Diabetes and atherosclerosis: an epidemiologic view. Diab. Metab. Rev. 3: 463-524.
5. NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III). 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
6. HSUEH, W.A. et al. 2004. Insulin resistance and the endothelium. Am. J. Med. 117: 109-117.
7. GALL, M.A. et al. 1995. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44: 1303-1309.
8. BERTHEZONE, F. 2002. Diabetic dyslipidaemia. Br. J. Diab. Vasc. Dis. 2: S12-S17.
9. BAYS, H. 2003. Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and future treatment options. Br. J. Diab. Vasc. Dis. 3: 356-360.
10. AMMAR, R.F. et al. 2000. Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes. Cardiovasc. Res. 47: 595-601.
11. MCVEIGH, G.E. et al. 1992. Impaired endothelium-dependent and -independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 771-776.
12. MAKIMATTILA, S. et al. 1999. Impaired endothelium dependent vasodilation in type 2 diabetes. Diabetes Care 22: 973-981.
13. CALLES-ESCANDON, J. & M. CIPOLLA 2001. Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. 2: 36-52.
14. AYDIN, A. et al. 2001. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin. Biochem. 34: 65-70.
15. ABRAMS, J. 1997. Role of endothelial dysfunction in coronary artery disease. Am. J. Cardiol. 79: 2-9.
16. RECASENS, M. et al. 2005. An inflammation score is better associated with basal than stimulated surrogate indexes of insulin resistance. J. Clin. Endocrinol. Metab. 90: 112-116.
17. FERNANDEZ-REAL, J.M. et al. 2000. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49: 517-520.
18. MISHIMA, Y. et al. 2001. Relationship between serum tumor necrosis factor-[alpha] and insulin resistance in obese men with Type 2 diabetes mellitus. Diab. Res. Clin. Pract. 52: 119-123.
19. LIN, S.-Y. et al. 2004. Increased serum soluble tumor necrosis factor receptor levels are associated with insulin resistance in liver cirrhosis. Metabolism 53: 922-926.
20. MCLAUGHLIN, T. et al. 2002. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106: 2908-2912.
21. MOHAMED-ALI, V. et al. 1997. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-{alpha}, in vivo. J. Clin. Endocrinol. Metab. 82: 4196-4200.
22. HOTAMISLIGIL, G.S. et al. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
23. YUDKIN, J.S. et al. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19: 972-978.
24. WINKLER, G. et al. 2003. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur. J. Endocrinol. 149: 129-135.
25. HAK, A.E. et al. 1999. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy middle-aged women. Arterioscler. Thromb. Vasc. Biol. 19: 1986-1991.
26. ERBAGCI, A.B. et al. 2002. Mediators of inflammation in children with type 2 diabetes mellitus: cytokines in type 1 diabetic children. Clin. Biochem. 34: 645-650.
27. RAPOPORT, M.J. et al. 1998. Decreased secretion of Th2 cytokines precedes upregulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J. Autoimmun. 11: 635-642.
28. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865.
29. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. 1998. Intensive blood-glucose control with sulphonylureas or insulin comparedwith conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
30. LYONS, T.J. et al. 1991. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J. Clin. Invest. 87: 1910-1915.
31. HSUEH, W.A. et al. 2004. Insulin resistance and the endothelium. Am. J. Med. 117: 109-117.
32. GALL, M.A. et al. 1995. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44: 1303-1309.
33. DYER, D.G. et al. 1993. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 91: 2463-2469.
34. MCCANCE, D.R. et al. 1993. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 91: 2470-2478.
35. BERTHEZONE, F. 2002. Diabetic dyslipidaemia. Br. J. Diabetes. Vasc. Dis. 2: S12-S17.
36. REAVEN, G.M. 2000. Insulin resistance: how important is it to treat? Exp. Clin. Endocrinol. Diabetes 108: S274-S280.
37. BAYS, H. 2003. Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and future treatment options. Br. J. Diab. Vasc. Dis. 3: 356-360.
38. BRUNZELL, J.D. & A.F. AYYOBI. 2003. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am. J. Med. 115: S24-S28.
39. FONSECA, V.A. 2003. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am. J. Cardiol. 92: J50-J60.
40. MAKIMATTILA, S. & H. YKI-JDRVINEN. 2002. Endothelial dysfunction in human diabetes. Curr. Diab. Rep. 2: 26-36.
41. PICKUP, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823.
42. HSUEH, W.A. & D. BRUEMMER. 2004. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43: 297-305.
43. EINHORN, D. et al. 2004. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol. Metab. Clin. North Am. 33: 595-616.
44. HAFFNER, S.M. 2003. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diab. Res. Clin. Pract. 61: S9-S18.
45. NESTO, R. 2004. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease and the effects of insulinsensitizing treatment with thiazolidinediones. Diabet. Med. 21: 810-817.
46. KULLER, L.H. et al. 1996. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144: 537-547.
47. RIDKER, P.M. et al. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336: 973-979.
48. TAN, S.A. & L.G. TAN 2004. Synergistic effects of simvastatin and pioglitazone on inflammatory cytokines interferon-gamma, tumor necrosis factoralpha, interleukin-6 and C-reactive protein in diabetic patients with hyperlipidemia and coronary artery disease [abstract 58]. Endocr. Pract. 10(Suppl 1): 21.
49. CHARBONNEL, B. et al. 2004. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27: 1647-1653.
50. MALINOW, M. et al. 1999. Homocysteine, diet and cardiovascular diseases a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99: 178-182.